|

A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors

RECRUITINGEarly 1Sponsored by Peking Union Medical College Hospital
Actively Recruiting
PhaseEarly 1
SponsorPeking Union Medical College Hospital
Started2024-08-01
Est. completion2025-12-20
Eligibility
Age18 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06632860

Summary

The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. Integrin αvβ3 is highly expressed in some tumor cells and new blood vessels, making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels.68Ga-labeled DOTA-TATE-RGD is a new type of tumor-specific imaging agent developed by researchers based on the above foundation, which is used for targeted diagnosis and internal radiation therapy for patients with SSTR2 and αvβ3 positive tumors.

Eligibility

Age: 18 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* histologically confirmed various cancer patients;
* 68Ga-TATE-RGD and 18F-FDG PET/CT within a week;
* signed written consent.

Exclusion Criteria:

* known allergy against TATE-RGD;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Conditions4

CancerIodine-resistant Thyroid CancerMeningiomaNETs

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.